These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 36671478)
1. PI3K-AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. Yuan Y; Long H; Zhou Z; Fu Y; Jiang B Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671478 [TBL] [Abstract][Full Text] [Related]
2. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. Tewari D; Patni P; Bishayee A; Sah AN; Bishayee A Semin Cancer Biol; 2022 May; 80():1-17. PubMed ID: 31866476 [TBL] [Abstract][Full Text] [Related]
3. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment. Narayanankutty A Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720 [TBL] [Abstract][Full Text] [Related]
4. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813 [TBL] [Abstract][Full Text] [Related]
5. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy. Narayanankutty A Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200 [TBL] [Abstract][Full Text] [Related]
6. Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer. Sharma V; Sharma AK; Punj V; Priya P Semin Cancer Biol; 2019 Dec; 59():133-146. PubMed ID: 31408722 [TBL] [Abstract][Full Text] [Related]
7. The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds. Roy T; Boateng ST; Uddin MB; Banang-Mbeumi S; Yadav RK; Bock CR; Folahan JT; Siwe-Noundou X; Walker AL; King JA; Buerger C; Huang S; Chamcheu JC Cells; 2023 Jun; 12(12):. PubMed ID: 37371141 [TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products. Iksen ; Pothongsrisit S; Pongrakhananon V Molecules; 2021 Jul; 26(13):. PubMed ID: 34279440 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of PI3K/Akt/mTOR signaling by natural products. Huang S Anticancer Agents Med Chem; 2013 Sep; 13(7):967-70. PubMed ID: 23272914 [No Abstract] [Full Text] [Related]
10. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling. Grunt TW; Mariani GL Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720 [TBL] [Abstract][Full Text] [Related]
11. PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation. Sharma VR; Gupta GK; Sharma AK; Batra N; Sharma DK; Joshi A; Sharma AK Curr Pharm Des; 2017; 23(11):1633-1638. PubMed ID: 27848885 [TBL] [Abstract][Full Text] [Related]
12. Role of regulatory miRNAs of the PI3K/AKT signaling pathway in the pathogenesis of breast cancer. Rahmani F; Ferns GA; Talebian S; Nourbakhsh M; Avan A; Shahidsales S Gene; 2020 May; 737():144459. PubMed ID: 32045660 [TBL] [Abstract][Full Text] [Related]
13. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer]. ; ; ; Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333 [TBL] [Abstract][Full Text] [Related]
14. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents. Sun H; Wang Z; Yakisich JS Anticancer Agents Med Chem; 2013 Sep; 13(7):1048-56. PubMed ID: 23293890 [TBL] [Abstract][Full Text] [Related]
15. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression. Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779 [TBL] [Abstract][Full Text] [Related]
16. Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy. Chamcheu JC; Roy T; Uddin MB; Banang-Mbeumi S; Chamcheu RN; Walker AL; Liu YY; Huang S Cells; 2019 Jul; 8(8):. PubMed ID: 31370278 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells. Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590 [TBL] [Abstract][Full Text] [Related]
18. PI3K/AKT/mTOR signaling pathway modulation by circular RNAs in breast cancer progression. Karami Fath M; Akhavan Masouleh R; Afifi N; Loghmani S; Tamimi P; Fazeli A; Mousavian SA; Falsafi MM; Barati G Pathol Res Pract; 2023 Jan; 241():154279. PubMed ID: 36584499 [TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Ciruelos Gil EM Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538 [TBL] [Abstract][Full Text] [Related]
20. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress. Bahrami A; Khazaei M; Shahidsales S; Hassanian SM; Hasanzadeh M; Maftouh M; Ferns GA; Avan A J Cell Biochem; 2018 Jan; 119(1):213-222. PubMed ID: 28513879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]